$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000101247720000009 Filed on May 11, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$12.24M	$16.44M
YoY Change	-25.52%	-50.63%
Cost Of Revenue	$2.457M	$3.266M
YoY Change	-24.77%	-50.46%
Gross Profit	$9.786M	$13.17M
YoY Change	-25.7%	-50.67%
Gross Profit Margin	79.93%	80.13%
Selling, General & Admin	$7.913M	$10.45M
YoY Change	-24.25%	-57.34%
% of Gross Profit	80.86%	79.31%
Research & Development	$5.530M	$7.329M
YoY Change	-24.55%	-26.35%
% of Gross Profit	56.51%	55.64%
Depreciation & Amortization	$460.0K	$370.0K
YoY Change	24.32%	-81.41%
% of Gross Profit	4.7%	2.81%
Operating Expenses	$13.44M	$17.78M
YoY Change	-24.37%	-48.39%
Operating Profit	-$6.497M	-$8.167M
YoY Change	-20.45%	-35.31%
Interest Expense	-$3.190M	-$3.060M
YoY Change	4.25%	91.25%
% of Operating Profit
Other Income/Expense, Net	-$310.0K	-$307.0K
YoY Change	0.98%	-22.28%
Pretax Income	-$10.38M	-$13.39M
YoY Change	-22.53%	-8.04%
Income Tax	-$9.510M	-$374.0K
% Of Pretax Income
Net Earnings	-$865.0K	-$13.02M
YoY Change	-93.36%	6.39%
Net Earnings / Revenue	-7.07%	-79.2%
Basic Earnings Per Share	-$0.02	-$0.35
Diluted Earnings Per Share	-$0.02	-$0.35
COMMON SHARES
Basic Shares Outstanding	41.06M shares	37.35M shares
Diluted Shares Outstanding	41.06M shares	37.35M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$113.5M	$79.90M
YoY Change	42.05%	-59.69%
Cash & Equivalents	$73.51M	$9.630M
Short-Term Investments	$40.00M	$70.20M
Other Short-Term Assets	$155.0K	$1.040M
YoY Change	-85.1%	-88.57%
Inventory	$3.523M	$4.258M
Prepaid Expenses	$1.933M	$2.607M
Receivables	$8.797M	$11.77M
Other Receivables	$2.600M	$2.400M
Total Short-Term Assets	$131.0M	$102.4M
YoY Change	27.86%	-55.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$472.0K	$1.749M
YoY Change	-73.01%	-35.75%
Goodwill	$18.49M	$18.49M
YoY Change	0.0%	0.0%
Intangibles	$610.0K	$1.428M
YoY Change	-57.28%	-98.03%
Long-Term Investments	$1.500M	$1.500M
YoY Change	0.0%	-55.88%
Other Assets	$47.52M	$36.12M
YoY Change	31.56%	78.47%
Total Long-Term Assets	$76.75M	$71.19M
YoY Change	7.82%	-40.64%
TOTAL ASSETS
Total Short-Term Assets	$131.0M	$102.4M
Total Long-Term Assets	$76.75M	$71.19M
Total Assets	$207.7M	$173.6M
YoY Change	19.64%	-50.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.790M	$4.150M
YoY Change	63.61%	-73.91%
Accrued Expenses	$14.86M	$14.69M
YoY Change	1.15%	-68.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$104.0K
YoY Change	-100.0%	-8.77%
Total Short-Term Liabilities	$32.34M	$31.36M
YoY Change	3.12%	-64.03%
LONG-TERM LIABILITIES
Long-Term Debt	$123.3M	$117.2M
YoY Change	5.19%	4.88%
Other Long-Term Liabilities	$5.664M	$12.58M
YoY Change	-54.97%	-11.75%
Total Long-Term Liabilities	$128.9M	$129.8M
YoY Change	-0.64%	3.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.34M	$31.36M
Total Long-Term Liabilities	$128.9M	$129.8M
Total Liabilities	$175.7M	$183.2M
YoY Change	-4.12%	-30.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$392.1M	-$371.0M
YoY Change	5.68%	34.95%
Common Stock	$497.8M	$434.6M
YoY Change	14.53%	1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$50.00M	$50.00M
YoY Change	0.0%	17.44%
Treasury Stock Shares	5.407M shares	5.407M shares
Shareholders Equity	$32.07M	-$9.582M
YoY Change
Total Liabilities & Shareholders Equity	$207.7M	$173.6M
YoY Change	19.64%	-50.66%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$865.0K	-$13.02M
YoY Change	-93.36%	6.39%
Depreciation, Depletion And Amortization	$460.0K	$370.0K
YoY Change	24.32%	-81.41%
Cash From Operating Activities	-$11.64M	-$21.21M
YoY Change	-45.13%	17.76%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$30.00K
YoY Change	-100.0%	-26.83%
Acquisitions
YoY Change
Other Investing Activities	$13.23M	$21.42M
YoY Change	-38.24%	-126.54%
Cash From Investing Activities	$13.23M	$21.39M
YoY Change	-38.17%	-126.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	$62.21M	$92.00K
YoY Change	67519.57%	-99.93%
NET CHANGE
Cash From Operating Activities	-$11.64M	-$21.21M
Cash From Investing Activities	$13.23M	$21.39M
Cash From Financing Activities	$62.21M	$92.00K
Net Change In Cash	$63.73M	$305.0K
YoY Change	20795.74%	-98.74%
FREE CASH FLOW
Cash From Operating Activities	-$11.64M	-$21.21M
Capital Expenditures	$0.00	$30.00K
Free Cash Flow	-$11.64M	-$21.24M
YoY Change	-45.21%	17.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	6470000	USD
CY2019Q4	avdl	Accrued Contract Manufacturing Organization Liabilities AccruedContractManufacturingOrganizationLiabilities	735000	USD
CY2020Q1	avdl	Accrued Contract Manufacturing Organization Liabilities AccruedContractManufacturingOrganizationLiabilities	426000	USD
CY2019Q4	avdl	Accrued Contract Research Organization Charges AccruedContractResearchOrganizationCharges	2098000	USD
CY2020Q1	avdl	Accrued Contract Research Organization Charges AccruedContractResearchOrganizationCharges	1802000	USD
CY2019Q4	avdl	Accrued Social Charges AccruedSocialCharges	592000	USD
CY2020Q1	avdl	Accrued Social Charges AccruedSocialCharges	192000	USD
CY2020Q1	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	6200000	USD
CY2019Q1	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	2134000	USD
CY2020Q1	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	2478000	USD
CY2020Q1	avdl	Business Combination Financing Related Costs BusinessCombinationFinancingRelatedCosts	310000	USD
CY2020Q1	avdl	Coronavirus Aid Relief And Economic Security Act Cares Act Changein Tax Rate Deferred Tax Liability Income Tax Benefit CoronavirusAidReliefAndEconomicSecurityActCARESActChangeinTaxRateDeferredTaxLiabilityIncomeTaxBenefit	9124000	USD
CY2019Q1	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	3181000	USD
CY2020Q1	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	1774000	USD
CY2019Q1	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	307000	USD
CY2020Q1	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	310000	USD
CY2020Q1	avdl	Foodand Drug Administration Approval Number Of Products FoodandDrugAdministrationApprovalNumberOfProducts	3	FDA_drug
CY2020Q1	avdl	Guarantee Asset Current Carrying Value GuaranteeAssetCurrentCarryingValue	1708000	USD
CY2019Q4	avdl	Guarantee Current GuaranteeCurrent	454000	USD
CY2020Q1	avdl	Guarantee Current GuaranteeCurrent	456000	USD
CY2019Q4	avdl	Guarantee Noncurrent GuaranteeNoncurrent	1367000	USD
CY2020Q1	avdl	Guarantee Noncurrent GuaranteeNoncurrent	1252000	USD
CY2019Q1	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	449000	USD
CY2020Q1	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-160000	USD
CY2019Q1	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	94000	USD
CY2020Q1	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	276000	USD
CY2019Q1	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	147000	USD
CY2020Q1	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	872000	USD
CY2020Q1	avdl	Maximum Aggregate Offering Priceof American Depositary Shares Under Shelf Registration MaximumAggregateOfferingPriceofAmericanDepositarySharesUnderShelfRegistration	50000	USD
CY2020Q1	avdl	Maximum Aggregate Offering Priceof Securities Under Shelf Registration MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration	250000	USD
CY2020Q1	avdl	Maximum Threshold Percentage For Trigger Of Convertible Preferred Stock MaximumThresholdPercentageForTriggerOfConvertiblePreferredStock	0.0999
CY2019Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	6428000	USD
CY2020Q1	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	6362000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1151000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	758000	USD
CY2019Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	575000	USD
CY2020Q1	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	573000	USD
CY2020Q1	avdl	Percentage Of Royalty Payable On Net Sales PercentageOfRoyaltyPayableOnNetSales	0.15
CY2019Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	2107000	USD
CY2020Q1	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	1835000	USD
CY2019Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	6322000	USD
CY2020Q1	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	6288000	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001012477
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58129037	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	AVADEL PHARMACEUTICALS PLC
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6100000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6790000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8281000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8797000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19810000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14858000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22806000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23627000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	434391000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	497249000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	351000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	742000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1445000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1573000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	201000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	203000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19762	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15858	shares
CY2019Q4	us-gaap	Assets Assets	151436000	USD
CY2020Q1	us-gaap	Assets Assets	207725000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	82380000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	130975000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	420000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53238000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39977000	USD
CY2019Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2134000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2457000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	24604000	USD
CY2020Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2478000	USD
CY2018Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	28840000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	18740000	USD
CY2019Q4	us-gaap	Customer Refund Liability Noncurrent CustomerRefundLiabilityNoncurrent	981000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	39639000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	54384000	USD
CY2019Q1	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	27593000	USD
CY2019Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	17327000	USD
CY2020Q1	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	18050000	USD
CY2020Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9774000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73506000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9325000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9630000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9774000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73506000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	305000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63732000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42720000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42857000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37313000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37450000	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	429000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	518000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12805000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1686000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3266000	USD
CY2020Q1	us-gaap	Customer Refund Liability Noncurrent CustomerRefundLiabilityNoncurrent	1210000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	3136000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	112000	USD
CY2019Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-2673000	USD
CY2020Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-222000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8440000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	29427000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	37860000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	369000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	456000	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-1750000	USD
CY2020Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5554000	USD
CY2020Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5855000	USD
CY2019Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	11773000	USD
CY2020Q1	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	12195000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	29000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-68000	USD
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.027
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.917
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	813000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	18491000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	18491000	USD
CY2019Q4	us-gaap	Goodwill Gross GoodwillGross	18491000	USD
CY2020Q1	us-gaap	Goodwill Gross GoodwillGross	18491000	USD
CY2019Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2020Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2020Q1	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	1713000	USD
CY2019Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	1372000	USD
CY2020Q1	us-gaap	Guaranty Liabilities GuarantyLiabilities	1256000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13392000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10375000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-374000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9510000	USD
CY2019Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	72000	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	536000	USD
CY2020Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	536000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	752000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1187000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1021000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	517000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-46000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2253000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4750000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4905000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-467000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-47000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	813000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	610000	USD
CY2019Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3062000	USD
CY2020Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3190000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	1818000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	3148000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	3234000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3228000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	3234000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3020000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-899000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2845000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3570000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	3523000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	550000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	678000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	914000	USD
CY2020Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	348000	USD
CY2019Q1	us-gaap	Investment Income Net InvestmentIncomeNet	817000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	-378000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	180635000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	175658000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151436000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	207725000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35984000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	32336000	USD
CY2019Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2441000	USD
CY2020Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2788000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	121686000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	123258000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	121686000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	123258000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	1477000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	1477000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	54384000	USD
CY2020Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	39977000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62210000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21390000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13226000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21206000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11636000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-13018000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-865000	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8167000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6497000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	645000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	604000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2319000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2205000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3612000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3365000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3022000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2809000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	107000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	155000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	39274000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	47524000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	374000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-644000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	18000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	49000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-161000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8873000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	5000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4264000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3337000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2116000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1933000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	60733000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	92000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-177000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	213000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-821000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	213000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-821000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3832000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1932000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5664000	USD
CY2019Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	55000	USD
CY2020Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	55000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-307000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-310000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-541000	USD
CY2020Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	573000	USD
CY2019Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	507000	USD
CY2020Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	291000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	340000	USD
CY2019Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	3688000	USD
CY2020Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2065000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13444000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1562000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1477000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	34864000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	14788000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	544000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7329000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5530000	USD
CY2019Q1	us-gaap	Restructuring Charges RestructuringCharges	1228000	USD
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	159000	USD
CY2019Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2949000	USD
CY2020Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1705000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391215000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-392080000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16437000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12243000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10446000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7913000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	351000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	742000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	92000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	88000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60733000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1389000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2780000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-9582000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-29199000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	32067000	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	43000	USD
CY2020Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	2297000	USD
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5407000	shares
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	5407000	shares
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	49998000	USD
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	49998000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6465000	USD
CY2020Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3143000	USD
CY2019Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1051000	USD
CY2020Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	257000	USD
CY2019Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2020Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37354000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41057000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37354000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41057000	shares
CY2019Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	3944000	USD
CY2020Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1724000	USD

Files In Submission

Name	View Source	Status
0001012477-20-000009-index-headers.html	Edgar Link	pending
0001012477-20-000009-index.html	Edgar Link	pending
0001012477-20-000009.txt	Edgar Link	pending
0001012477-20-000009-xbrl.zip	Edgar Link	pending
avdl-20200331.xml	Edgar Link	completed
avdl-20200331.xsd	Edgar Link	pending
avdl-20200331_cal.xml	Edgar Link	unprocessable
avdl-20200331_def.xml	Edgar Link	unprocessable
avdl-20200331_lab.xml	Edgar Link	unprocessable
avdl-20200331_pre.xml	Edgar Link	unprocessable
avdl2020q1.htm	Edgar Link	pending
exhibit311q12020.htm	Edgar Link	pending
exhibit312q12020.htm	Edgar Link	pending
exhibit321q12020.htm	Edgar Link	pending
exhibit322q12020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2020 Q1 Form 10-Q Financial Statement

#000101247720000009 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2020 Q1 Form 10-Q Financial Statement

#000101247720000009 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl